Akorn Inc (AKRX.O)
22 Sep 2017
Latest Key Developments (Source: Significant Developments)
July 19 (Reuters) - Akorn Inc
April 24 (Reuters) - Akorn Inc
Akorn Inc: Q4 gaap earnings per share $0.26 . expects 2017 adjusted net income per diluted share (non-gaap) $1.53 - $1.72 . Akorn provides fourth quarter and full year 2016 results and outlines full year 2017 guidance . Q4 revenue $284 million versus i/b/e/s view $288 million . Q4 earnings per share view $0.57 -- Thomson Reuters I/B/E/S . Q4 adjusted non-gaap earnings per share $0.58 including items . sees 2017 consolidated revenue, $ 1,010 million- $ 1,060 million . Akorn's guidance includes $30 to $60 million from new product launches of products already approved and those expected to be approved in 2017 . sees 2017 gaap net income per diluted share $0.99 -$1.18 . sees 2017 adjusted net income per diluted share (non-gaap) $1.53- $1.72 .Fy2017 earnings per share view $2.17, revenue view $1.12 billion -- Thomson Reuters I/B/E/S. Full Article
Akorn, Inc:Says Duane A. Portwood, will join Akorn as Executive Vice President and Chief Financial Officer, effective October 30, 2015.Interim Chief Financial Officer Randall Pollard will continue to serve as Senior Vice President, Chief Accounting Officer and Corporate Controller after Portwood's appointment. Full Article
BOSTON U.S. prosecutors have identified Insys Therapeutics Inc's billionaire founder as an unindicted co-conspirator in a case accusing six former executives and managers of participating in a scheme that involved bribing doctors to prescribe a fentanyl-based drug, according to a court document.